Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Steven D. Miller net worth and biography

Steven Miller Biography and Net Worth

Director of Bausch Health Companies

Mr. Miller was appointed to the Board on March 17, 2021. Since October 2020, he has been a portfolio manager for Icahn Capital LP, a subsidiary of Icahn Enterprises L.P., a diversified holding company engaged in a variety of businesses. Prior to joining Icahn Capital L.P., Mr. Miller was an analyst in the Distressed and Special Situations investment group in the New York office of BlueMountain Capital Management, LLC from 2013 to 2019. Mr. Miller represented BlueMountain on the Ad Hoc Group of Puerto Rico Electric Power Authority Bondholders from 2014 to 2019, and from 2011 to 2013 he was an analyst in the Distressed Products Group in the New York office of Goldman, Sachs & Co. Mr. Miller received a B.S. summa cum laude from Duke University in 2011. He has been a director of Conduent Incorporated since February 2021.

How do I contact Steven D. Miller?: The corporate mailing address for Mr. Miller and other Bausch Health Companies executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Companies can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on Steven D. Miller's contact information.
Has Steven D. Miller been buying or selling shares of Bausch Health Companies?: Steven D. Miller has not been actively trading shares of Bausch Health Companies within the last three months. Most recently, on Tuesday, November 30th, Steven D. Miller bought 50,000 shares of Bausch Health Companies stock. The stock was acquired at an average cost of $24.24 per share, with a total value of $1,212,000.00. Learn More on Steven D. Miller's trading history.
Who are Bausch Health Companies' active insiders?: Bausch Health Companies' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Companies' active insiders.
Are insiders buying or selling shares of Bausch Health Companies?: In the last year, insiders at the sold shares 2 times. They sold a total of 13,590 shares worth more than $84,651.30. The most recent insider tranaction occured on September, 6th when EVP Seana Carson sold 13,370 shares worth more than $83,027.70. Insiders at Bausch Health Companies own 8.1% of the company. Learn More about insider trades at Bausch Health Companies.
Information on this page was last updated on 9/6/2024.

Steven D. Miller Insider Trading History at Bausch Health Companies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/30/2021	Buy	50,000	$24.24	$1,212,000.00

Steven D. Miller Buying and Selling Activity at Bausch Health Companies

Bausch Health Companies Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $8.48

$8.47

$8.73

50 Day Range

MA: $8.18

$6.19

$9.78

2 Week Range

Now: $8.48

$3.96

$11.46

Volume

1,027,632 shs

Average Volume

2,020,304 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74